论文部分内容阅读
目的探讨玻璃体腔注射雷珠单抗对病理性近视脉络膜新生血管(PM-CNV)患者疗效的影响。方法选取2013年1月至2016年1月于抚顺市眼病医院治疗的48例病理性近视PM-CNV患者作为研究对象,按随机数字表法将其分为观察组和对照组,各24例。观察组患者使用玻璃体腔注射雷珠单抗方法进行治疗,对照组患者常规给予静脉注射血栓通及口服腺苷钴胺片治疗,比较两组患者的治疗效果。结果治疗后,观察组患者的最佳矫正视力(BCVA)明显高于对照组,黄斑中心厚度(CMT)明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者总不良事件发生率明显低于对照组,差异有统计学意义(P<0.05);观察组患者治疗的总优良率明显高于对照组,差异有统计学意义(P<0.05)。结论玻璃体腔注射雷珠单抗对病理性近视PM-CNV患者的治疗效果较好,能够有效降低不良事件发生率,安全性较高。
Objective To investigate the effect of intravitreal injection of ranibizumab on the curative effect of patients with pathologic myopia choroidal neovascularization (PM-CNV). Methods 48 cases of pathological myopia PM-CNV patients treated in Fushun Eye Hospital from January 2013 to January 2016 were selected as study objects, divided into observation group and control group according to random number table method, 24 cases in each group. Patients in the observation group were treated with intravitreal injection of ranibizumab. Patients in the control group were given routine intravenous thromboxane and oral adenosine cobalamin tablets, and the treatment effect was compared between the two groups. Results After treatment, the best corrected visual acuity (BCVA) of the observation group was significantly higher than that of the control group, and the macular center thickness (CMT) was significantly lower than that of the control group (all P <0.05) The incidence of adverse events was significantly lower than that of the control group (P <0.05). The total excellent rate of treatment in the observation group was significantly higher than that of the control group (P <0.05). Conclusion Intravitreal injection of ranibizumab in patients with pathological myopia PM-CNV treatment is better, can effectively reduce the incidence of adverse events, high safety.